Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 11/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ESRRA | P11474 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107574 | 1.00 | KMT2A (0.40) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4107569 | 1.00 | KMT2A (0.40) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4106780 | 0.90 | MEN1 (0.42) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4106787 | 0.90 | MEN1 (0.42) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13847342 | 0.90 | MEN1 (0.42) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4107586 | 0.89 | HPGD (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL12892318 | 0.82 | MEN1 (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL1248238 | 0.82 | MEN1 (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL1248237 | 0.82 | MEN1 (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL12892118 | 0.82 | MEN1 (0.47) | KMT2AMEN1SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | KMT2A 4327/4885MEN1 912/4885SMN1; SMN2 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.